Pub Date : 2023-09-23DOI: 10.9734/ca/2023/v12i4364
Francis C. Ifiora, Ginikachukwu M. Agudosi, Chinwendum U. Ekpemiro, Valentine C. Keke, Pedro Okoh, Abiola Y. Oyesile, Linda A. Mbah, Ngozi T. Akueme, Oyewole Emmanuel Akanle, Romanus Anebere, Moses, Chukwuebuka Odoeke, Yetunde Ishola, Okelue E. Okobi
Background: AF's global prevalence underscores its significance as a cardiac rhythm disorder that disrupts atrial activity, impairing normal cardiac function. Over five decades of study have illuminated the pathophysiological mechanisms underlying AF, including insights into re-entrant waves and macro-reentrant circuits. The emergence of non-uniform conduction patterns and bidirectional block regions has further enriched our understanding. Risk factors contributing to AF development encompass cardiovascular conditions, advanced age, and atrial structural changes. With its implications on stroke risk and cardiovascular health, AF has become a growing public health concern. The focus on AF epidemiology has expanded, with attention on the relationship between left atrial size and AF development. Individuals with larger left atria exhibit a heightened risk. Additionally, the elevated stroke risk associated with AF has been consistently documented. To optimize clinical management, distinctions are drawn between chronic and paroxysmal AF, as well as the presence of structural heart disease. Mapping techniques have revealed insights into "atrial remodeling" and AF pathology. In managing AF, controlling heart rate, preventing clot formation, and restoring sinus rhythm are principal objectives. This article categorizes AF into acute, chronic, stable, or unstable forms, tailoring management approaches accordingly. While pharmacological interventions have shown efficacy, their limitations drive the exploration of nonpharmacological strategies. Approaches range from medications to cardioversion, including electrical and pharmacological methods. Objective: This paper aimed to provide a comprehensive exploration of non-pharmacological approaches to AF management. Methodology: This paper employed a structured methodology. This method involved a literature review, data synthesis, and critical analysis. During the literature review phase, we systematically searched electronic databases (PubMed, MEDLINE, Embase, and Google Scholar) for studies published from 1960 to 2023. Specific keywords and phrases such as "atrial fibrillation," "non-pharmacological interventions," "electrical cardioversion," "catheter ablation," "lifestyle modifications," "autonomic modulation," "left atrial appendage closure," and "exercise" were used. Our inclusion criteria encompassed studies addressing various non-pharmacological approaches for AF management, including observational studies and randomized controlled trials. Result: The initial stage of our study involved the identification of a substantial number of relevant studies. We conducted a thorough literature search across multiple databases, using specific search terms and criteria relevant to our research topic. This comprehensive search yielded a total of 1,200 studies. After applying these stringent filtering criteria, we were left with 350 studies. To further refine our final sample and categorize the studies accordin
{"title":"Nonpharmacological Approach to Managing Atrial Fibrillation: A Review","authors":"Francis C. Ifiora, Ginikachukwu M. Agudosi, Chinwendum U. Ekpemiro, Valentine C. Keke, Pedro Okoh, Abiola Y. Oyesile, Linda A. Mbah, Ngozi T. Akueme, Oyewole Emmanuel Akanle, Romanus Anebere, Moses, Chukwuebuka Odoeke, Yetunde Ishola, Okelue E. Okobi","doi":"10.9734/ca/2023/v12i4364","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4364","url":null,"abstract":"Background: AF's global prevalence underscores its significance as a cardiac rhythm disorder that disrupts atrial activity, impairing normal cardiac function. Over five decades of study have illuminated the pathophysiological mechanisms underlying AF, including insights into re-entrant waves and macro-reentrant circuits. The emergence of non-uniform conduction patterns and bidirectional block regions has further enriched our understanding. Risk factors contributing to AF development encompass cardiovascular conditions, advanced age, and atrial structural changes. With its implications on stroke risk and cardiovascular health, AF has become a growing public health concern. The focus on AF epidemiology has expanded, with attention on the relationship between left atrial size and AF development. Individuals with larger left atria exhibit a heightened risk. Additionally, the elevated stroke risk associated with AF has been consistently documented. To optimize clinical management, distinctions are drawn between chronic and paroxysmal AF, as well as the presence of structural heart disease. Mapping techniques have revealed insights into \"atrial remodeling\" and AF pathology. In managing AF, controlling heart rate, preventing clot formation, and restoring sinus rhythm are principal objectives. This article categorizes AF into acute, chronic, stable, or unstable forms, tailoring management approaches accordingly. While pharmacological interventions have shown efficacy, their limitations drive the exploration of nonpharmacological strategies. Approaches range from medications to cardioversion, including electrical and pharmacological methods. Objective: This paper aimed to provide a comprehensive exploration of non-pharmacological approaches to AF management. Methodology: This paper employed a structured methodology. This method involved a literature review, data synthesis, and critical analysis. During the literature review phase, we systematically searched electronic databases (PubMed, MEDLINE, Embase, and Google Scholar) for studies published from 1960 to 2023. Specific keywords and phrases such as \"atrial fibrillation,\" \"non-pharmacological interventions,\" \"electrical cardioversion,\" \"catheter ablation,\" \"lifestyle modifications,\" \"autonomic modulation,\" \"left atrial appendage closure,\" and \"exercise\" were used. Our inclusion criteria encompassed studies addressing various non-pharmacological approaches for AF management, including observational studies and randomized controlled trials. Result: The initial stage of our study involved the identification of a substantial number of relevant studies. We conducted a thorough literature search across multiple databases, using specific search terms and criteria relevant to our research topic. This comprehensive search yielded a total of 1,200 studies. After applying these stringent filtering criteria, we were left with 350 studies. To further refine our final sample and categorize the studies accordin","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"149 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135959864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-16DOI: 10.9734/ca/2023/v12i4363
Abdessamad Couissi, Taha Ettachfini, Mehdi Rochd, Anass Maaroufi, Meryem Haboub, Rachida Habbal
Aims: We aimed to investigate the prognostic value of the tricuspid annular plane systolic excursion (TAPSE)/ pulmonary arterial systolic pressure (PASP) ratio in Moroccan patients with heart Failure (HF).
Study Design: A retrospective study was conducted in The Cardiology Department of Ibn Rochd Hospital of Casablanca in Morocco. The study was conducted in the period between March 2012 to March 2016 with a follow-up until December 2022.
Methods: data were evaluated from the HF register patients and their relatives were contacted by phone. Patients with reduced LVEF were included, patients with pulmonary embolism, and patients with HFpEF were excluded. The endpoint of the study was mortality.
Results: 128 patients were enrolled Over an average follow-up of 58 months. 51(41.4%) patients died at the end of the follow-up, the median value of left ventricular ejection fraction was 35.2 ± 2.2%. Patients were stratified according to the TAPSE/PASP ratio (low <0.32 mm/mmHg; high: >0.32 mm/mmHg). Kaplan-Meier survival analysis showed that ten-year all-cause mortality was significantly higher in patients with TAPSE/PASP ≤0.32 mm/mmHg than in patients with TAPSE/PASP > 0.32 mm/mmHg (log-rank 7.8, p =0.008) Cox regression analysis revealed that lower LVEF (p= 0.04), and a ratio of TAPSEPAPS <0.32 (p=0.02) were associated to an increase in all-cause mortality.
Conclusion: Correlating right ventricular function to loading conditions may be more accurate in assessing its real contractility and predicting patients’ outcomes. Our study showed that TAPSE/PASP appears as a novel prognostic predictor in patients with Heart failure.
{"title":"Tricuspid Annular Plane Systolic Excursion/Pulmonary Arterial Systolic Pressure Ratio as a Predictor of Mortality in Heart Failure Patients","authors":"Abdessamad Couissi, Taha Ettachfini, Mehdi Rochd, Anass Maaroufi, Meryem Haboub, Rachida Habbal","doi":"10.9734/ca/2023/v12i4363","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4363","url":null,"abstract":"Aims: We aimed to investigate the prognostic value of the tricuspid annular plane systolic excursion (TAPSE)/ pulmonary arterial systolic pressure (PASP) ratio in Moroccan patients with heart Failure (HF). 
 Study Design: A retrospective study was conducted in The Cardiology Department of Ibn Rochd Hospital of Casablanca in Morocco. The study was conducted in the period between March 2012 to March 2016 with a follow-up until December 2022.
 Methods: data were evaluated from the HF register patients and their relatives were contacted by phone. Patients with reduced LVEF were included, patients with pulmonary embolism, and patients with HFpEF were excluded. The endpoint of the study was mortality.
 Results: 128 patients were enrolled Over an average follow-up of 58 months. 51(41.4%) patients died at the end of the follow-up, the median value of left ventricular ejection fraction was 35.2 ± 2.2%. Patients were stratified according to the TAPSE/PASP ratio (low <0.32 mm/mmHg; high: >0.32 mm/mmHg). Kaplan-Meier survival analysis showed that ten-year all-cause mortality was significantly higher in patients with TAPSE/PASP ≤0.32 mm/mmHg than in patients with TAPSE/PASP > 0.32 mm/mmHg (log-rank 7.8, p =0.008) Cox regression analysis revealed that lower LVEF (p= 0.04), and a ratio of TAPSEPAPS <0.32 (p=0.02) were associated to an increase in all-cause mortality. 
 Conclusion: Correlating right ventricular function to loading conditions may be more accurate in assessing its real contractility and predicting patients’ outcomes. Our study showed that TAPSE/PASP appears as a novel prognostic predictor in patients with Heart failure.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135308478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-12DOI: 10.9734/ca/2023/v12i4362
M. Njie, P. M. Mulendele, M. Selmaoui, M. Jiddou, A. Assklou, M. Haboub, A. Drighil, R. Habbal
Background: Isolated pulmonary valve endocarditis (PVE) is a rare condition that accounts for 1.5–2% of all reported cases of endocarditis. Herein, we describe a rare case of isolated pulmonary valve endocarditis with a fortuitous discover of a congenital heart disease in a young adult subject. Unlike other cases of right sided endocarditis, we treated our patient both medically and surgically.
Case Presentation: The patient was diagnosed with an isolated pulmonary valve endocarditis after blood cultures confirming the presence of Abiotrophia defectiva, a germ difficult to cultivate whilst the echocardiographic revealed a vegetation mass measuring 8mm long alongside with the discovery of a severe pulmonary valve stenosis and a large atrial septal defect (ASD) of 39mm wide. Septic pulmonary emboli were the first clinical manifestation in our patient. Both medical and surgical treatment was indicated based on dual antibiotics, removal of the vegetation, valvulotomy and closure of the ASD.
Conclusion: Both medical and early surgery therapy should be considered in patient with right sided endocarditis associated with congenital heart disease for better clinical outcome.
{"title":"Isolated Pulmonary Valve Endocarditis on an Undiagnosed Congenital Heart Disease in a Young Adult: A Rare Clinical Entity","authors":"M. Njie, P. M. Mulendele, M. Selmaoui, M. Jiddou, A. Assklou, M. Haboub, A. Drighil, R. Habbal","doi":"10.9734/ca/2023/v12i4362","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4362","url":null,"abstract":"Background: Isolated pulmonary valve endocarditis (PVE) is a rare condition that accounts for 1.5–2% of all reported cases of endocarditis. Herein, we describe a rare case of isolated pulmonary valve endocarditis with a fortuitous discover of a congenital heart disease in a young adult subject. Unlike other cases of right sided endocarditis, we treated our patient both medically and surgically.
 Case Presentation: The patient was diagnosed with an isolated pulmonary valve endocarditis after blood cultures confirming the presence of Abiotrophia defectiva, a germ difficult to cultivate whilst the echocardiographic revealed a vegetation mass measuring 8mm long alongside with the discovery of a severe pulmonary valve stenosis and a large atrial septal defect (ASD) of 39mm wide. Septic pulmonary emboli were the first clinical manifestation in our patient. Both medical and surgical treatment was indicated based on dual antibiotics, removal of the vegetation, valvulotomy and closure of the ASD.
 Conclusion: Both medical and early surgery therapy should be considered in patient with right sided endocarditis associated with congenital heart disease for better clinical outcome.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135827812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-12DOI: 10.9734/ca/2023/v12i4361
M. Naaim, F. Rebbouh, M. Eljamili, S. El Karimi, M. El Hattaoui
Acquired pulmonary stenosis in adults due to extrinsic compression of the pulmonary artery is a rare manifestation of non-Hodgkin’s lymphoma (NHL). The incidence remains poorly known in the literature since only a few sporadic cases are described.
The clinical management is directed towards the treatment of the underlying disease. According to the latter, the patient may benefit from chemotherapy, radiotherapy, angioplasty, stenting, or surgery.
We describe here the case of a young patient who was diagnosed with acquired extrinsic pulmonary stenosis secondary to a type B large cell lymphoma of mediastinal location. Our clinical case affirms the interest of a transthoracic echocardiogram in the diagnosis as well as the follow-up of this unusual manifestation.
{"title":"Acquired Extrinsic Pulmonary Stenosis Secondary to a Compressing Mediastinal Tumor","authors":"M. Naaim, F. Rebbouh, M. Eljamili, S. El Karimi, M. El Hattaoui","doi":"10.9734/ca/2023/v12i4361","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4361","url":null,"abstract":"Acquired pulmonary stenosis in adults due to extrinsic compression of the pulmonary artery is a rare manifestation of non-Hodgkin’s lymphoma (NHL). The incidence remains poorly known in the literature since only a few sporadic cases are described.
 The clinical management is directed towards the treatment of the underlying disease. According to the latter, the patient may benefit from chemotherapy, radiotherapy, angioplasty, stenting, or surgery.
 We describe here the case of a young patient who was diagnosed with acquired extrinsic pulmonary stenosis secondary to a type B large cell lymphoma of mediastinal location. Our clinical case affirms the interest of a transthoracic echocardiogram in the diagnosis as well as the follow-up of this unusual manifestation.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135878087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-06DOI: 10.9734/ca/2023/v12i4360
P. M. Mulendelé, M. Njie, M. Charfo, G. M. Lukifimpa, M. S. Boutar, B. E. Ovaga, M. Haboub, S. Arous, M. Benouna, A. Drighil, L. Azzouzi, R. Habbal
The emergence of immunotherapy and the gradual expansion of its indications in oncology will require particular vigilance to detect and quickly take care of the potential cardiac toxicities. They have improved prognosis and survival, including patients with kidney, lung or skin cancers (melanoma) and certain lymphomas. The incidence of unwanted cardiac events under immunotherapy is rare, undoubtedly less than 1 % under Ipilimab, Pembrolizumab and Nivolumab. Cardiac toxicity can be induced by many drugs but this time we focused on myocarditis induced by immuno-modulators, which is a rare but very fatal complication and has 2 main parts: an illustration of a clinical case and a review of the literature comprising generality, pathophysiology, clinical manifestations, diagnostic strategy and therapeutic management based on the guidelines of the European Society of cardiology on cardio-oncology recently published in 2022. Corticosteroids are drugs effective in the treatment of cardiac toxicity induced by immunotherapy.
{"title":"Myocarditis Induced by Immunotherapy: A Rare but Fatal Complication","authors":"P. M. Mulendelé, M. Njie, M. Charfo, G. M. Lukifimpa, M. S. Boutar, B. E. Ovaga, M. Haboub, S. Arous, M. Benouna, A. Drighil, L. Azzouzi, R. Habbal","doi":"10.9734/ca/2023/v12i4360","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4360","url":null,"abstract":"The emergence of immunotherapy and the gradual expansion of its indications in oncology will require particular vigilance to detect and quickly take care of the potential cardiac toxicities. They have improved prognosis and survival, including patients with kidney, lung or skin cancers (melanoma) and certain lymphomas. The incidence of unwanted cardiac events under immunotherapy is rare, undoubtedly less than 1 % under Ipilimab, Pembrolizumab and Nivolumab. Cardiac toxicity can be induced by many drugs but this time we focused on myocarditis induced by immuno-modulators, which is a rare but very fatal complication and has 2 main parts: an illustration of a clinical case and a review of the literature comprising generality, pathophysiology, clinical manifestations, diagnostic strategy and therapeutic management based on the guidelines of the European Society of cardiology on cardio-oncology recently published in 2022. Corticosteroids are drugs effective in the treatment of cardiac toxicity induced by immunotherapy.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"33 6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116469449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-02DOI: 10.9734/ca/2023/v12i4359
Evbayekha O. Endurance, Okorare Ovie, Gabriel Alugba, Anthony Willie, A. Y. Oyesile, Ede Omosumwen, C. M. Emeasoba, B. H. Salaudeen, Anita Ogochukwu Onyekwere, A. V. Agho, Omolola Okunromade, A. K. Busari, A. O. Akinsete, E. Emore, I. Sanusi, Agunwa Nnaemeka, V. A. Odoma, L. Oji, E. Okobi, Ohikhuai E. Evidence, O. E. Okobi
Background: The outcomes of SARS-CoV-2 (COVID) hospitalizations and their association with myocardial injury and thrombosis were studied. We aimed to provide further insights into the impact of COVID-19 on modern-day healthcare. Methods: Retrospective analysis of the National Inpatient Sample 2020 database. We used the International Classification of Disease Code, Tenth Edition (ICD-10) to identify all hospitalizations with COVID-19. We then conducted a subgroup analysis of the population of interest: Those who also developed myocardial infarction, pulmonary embolism, and deep venous thrombosis. Results: 335,799 hospitalizations with COVID. Of these, 1.6% (5,355) were diagnosed with non-ST-segment myocardial infarction (COVNSTEMI) were identified. The mean age of COVID-19 hospitalizations was 71.7, with 60.50% males. The population prevalence included 53.10% Whites, 17.80% Blacks, 19.20% Hispanics, and 4.10% Asians. The average Length of stay (LOS) was 10 days, and 37.60% of patients died during hospitalization. The average cost of hospitalization (TOTCHG) was $156,633. The COVSTEMI group comprised 1,364 cases, with a mean age of 67.4, in-hospital mortality of 47.4%, and the mean TOTCHG was $177,600. The DVTCOV group comprised 2,869 cases, while the PECOV group had 4,828 cases. Male predominance was observed in both groups, with mean ages of 66 years in the DVTCOV group and 64 years in the PECOV group. The DVTCOV group had a LOS of 16 days, with 24.71% mortality, while the PECOV group had a LOS of 11 days, with 19.20% mortality. The average TOTCHG in the DVTCOV group was $248,900, whereas it was $145,378 in the PECOV group. Conclusion: Our study revealed significant mortality rates across different groups, including 38% in COVNSTEMI, 47% in COVSTEMI, 25% in DVTCOV, and 19% in PECOV. These findings highlight the severity of COVID-related complications and the substantial financial burden of hospitalization.
{"title":"Myocardial Infarction, Deep Venous Thrombosis and Pulmonary Embolism in COVID-19 Hospitalizations: Stats from the Nationwide Inpatient Sample 2020","authors":"Evbayekha O. Endurance, Okorare Ovie, Gabriel Alugba, Anthony Willie, A. Y. Oyesile, Ede Omosumwen, C. M. Emeasoba, B. H. Salaudeen, Anita Ogochukwu Onyekwere, A. V. Agho, Omolola Okunromade, A. K. Busari, A. O. Akinsete, E. Emore, I. Sanusi, Agunwa Nnaemeka, V. A. Odoma, L. Oji, E. Okobi, Ohikhuai E. Evidence, O. E. Okobi","doi":"10.9734/ca/2023/v12i4359","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4359","url":null,"abstract":"Background: The outcomes of SARS-CoV-2 (COVID) hospitalizations and their association with myocardial injury and thrombosis were studied. We aimed to provide further insights into the impact of COVID-19 on modern-day healthcare. \u0000Methods: Retrospective analysis of the National Inpatient Sample 2020 database. We used the International Classification of Disease Code, Tenth Edition (ICD-10) to identify all hospitalizations with COVID-19. We then conducted a subgroup analysis of the population of interest: Those who also developed myocardial infarction, pulmonary embolism, and deep venous thrombosis. \u0000Results: 335,799 hospitalizations with COVID. Of these, 1.6% (5,355) were diagnosed with non-ST-segment myocardial infarction (COVNSTEMI) were identified. The mean age of COVID-19 hospitalizations was 71.7, with 60.50% males. The population prevalence included 53.10% Whites, 17.80% Blacks, 19.20% Hispanics, and 4.10% Asians. The average Length of stay (LOS) was 10 days, and 37.60% of patients died during hospitalization. The average cost of hospitalization (TOTCHG) was $156,633. The COVSTEMI group comprised 1,364 cases, with a mean age of 67.4, in-hospital mortality of 47.4%, and the mean TOTCHG was $177,600. The DVTCOV group comprised 2,869 cases, while the PECOV group had 4,828 cases. Male predominance was observed in both groups, with mean ages of 66 years in the DVTCOV group and 64 years in the PECOV group. The DVTCOV group had a LOS of 16 days, with 24.71% mortality, while the PECOV group had a LOS of 11 days, with 19.20% mortality. The average TOTCHG in the DVTCOV group was $248,900, whereas it was $145,378 in the PECOV group. \u0000Conclusion: Our study revealed significant mortality rates across different groups, including 38% in COVNSTEMI, 47% in COVSTEMI, 25% in DVTCOV, and 19% in PECOV. These findings highlight the severity of COVID-related complications and the substantial financial burden of hospitalization.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129409025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-16DOI: 10.9734/ca/2023/v12i4358
Norah F. Aleid, Afnan M. Alsaad, Abdullah N. A. Alkhateeb, M. A. Soliman, Yazan H. Mustafa, A. Soliman, M. AlTaweel
Implantable cardioverter defibrillators (ICD) are widely used in primary prevention for cardiomyopathy patients. A 57-year-old male with dilated cardiomyopathy post ICD implantation was found to have an incidental asymptomatic echocardiogram finding of a mobile thrombus attached to the tip of the ICD wire in the right atrium. The thrombosis is probably due to a hypercoagulability state in patient with Cardiomyopathy and MALT lymphoma. The purpose of this case report is to highlight accidental discoveries of ICD wire thrombi and the appropriate therapeutic strategy.
{"title":"Incidental Detection of a Right atrial wire Attached Mobile Thrombus of an Implantable Cardioverter Defibrillator (ICD) in a Case of MALT Lymphoma","authors":"Norah F. Aleid, Afnan M. Alsaad, Abdullah N. A. Alkhateeb, M. A. Soliman, Yazan H. Mustafa, A. Soliman, M. AlTaweel","doi":"10.9734/ca/2023/v12i4358","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4358","url":null,"abstract":"Implantable cardioverter defibrillators (ICD) are widely used in primary prevention for cardiomyopathy patients. \u0000A 57-year-old male with dilated cardiomyopathy post ICD implantation was found to have an incidental asymptomatic echocardiogram finding of a mobile thrombus attached to the tip of the ICD wire in the right atrium. The thrombosis is probably due to a hypercoagulability state in patient with Cardiomyopathy and MALT lymphoma. The purpose of this case report is to highlight accidental discoveries of ICD wire thrombi and the appropriate therapeutic strategy.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116911767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-14DOI: 10.9734/ca/2023/v12i4357
I. Essaket, Assala Cherki, Mohammed El-Jamili, M. El-Hattaoui
Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disease of unknown origin with various clinical manifestations. In this article, we describe a case of 57-year-old presenting with Still's disease complicated by cardiac tamponade. This case highlights the importance of a prompt diagnosis of cardiac involvement in inflammatory diseases, as it can be fatal, and underlines the utility of echocardiographic evaluation not only in symptomatic patients, but also for the systematic detection of pericardial effusions. The case of hemodynamic compromise, it allows the provider to determine the timing, approach, and method of pericardial drainage due to cardiac tamponade being a very rare complication that requires an invasive approach.
{"title":"Adult Onset Still’s Disease Revealed by a Cardiac Tamponade: A Case Report","authors":"I. Essaket, Assala Cherki, Mohammed El-Jamili, M. El-Hattaoui","doi":"10.9734/ca/2023/v12i4357","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4357","url":null,"abstract":"Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disease of unknown origin with various clinical manifestations. In this article, we describe a case of 57-year-old presenting with Still's disease complicated by cardiac tamponade. \u0000This case highlights the importance of a prompt diagnosis of cardiac involvement in inflammatory diseases, as it can be fatal, and underlines the utility of echocardiographic evaluation not only in symptomatic patients, but also for the systematic detection of pericardial effusions. The case of hemodynamic compromise, it allows the provider to determine the timing, approach, and method of pericardial drainage due to cardiac tamponade being a very rare complication that requires an invasive approach.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"197 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115313026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-08DOI: 10.9734/ca/2023/v12i4356
M. Naaim, N. Malhabi, ,. M. Ztati, M. Eljamili, S. Karimi, M. E. Hattaoui
Orthostatic hypotension (OH) and supine hypertension (SH) are two cardiovascular symptoms of autonomic failure that frequently coexist in the same patient. Clinicians are faced with a dilemma because aggressive orthostatic intolerance treatment can exacerbate supine hypertension, and vice versa for supine hypertension management. The objective of our article is to provide a better framework for the clinical evaluation, the right choice of therapeutic options and the improvement of the quality of life of patients with OH-SH syndrome. For these reasons, we report three observations, whose etiologies, clinical presentation, and treatment are different, namely diabetes, multiple system atrophy type C (MSA) and Parkinson's disease.
{"title":"Syndrome of Orthostatic Hypotension with Supine Hypertension: A Therapeutic Dilemma for Cardiologists","authors":"M. Naaim, N. Malhabi, ,. M. Ztati, M. Eljamili, S. Karimi, M. E. Hattaoui","doi":"10.9734/ca/2023/v12i4356","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4356","url":null,"abstract":"Orthostatic hypotension (OH) and supine hypertension (SH) are two cardiovascular symptoms of autonomic failure that frequently coexist in the same patient. \u0000Clinicians are faced with a dilemma because aggressive orthostatic intolerance treatment can exacerbate supine hypertension, and vice versa for supine hypertension management. \u0000The objective of our article is to provide a better framework for the clinical evaluation, the right choice of therapeutic options and the improvement of the quality of life of patients with OH-SH syndrome. For these reasons, we report three observations, whose etiologies, clinical presentation, and treatment are different, namely diabetes, multiple system atrophy type C (MSA) and Parkinson's disease.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115376741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-18DOI: 10.9734/ca/2023/v12i4355
Mina Boutgourine, H. Nabawi, B. Maatof, Mohammed El-Jamili, Saloua El-Karimi, M. Hattaoui
Pulmonary Arterial Hypertension (PAH) is a clinical syndrome consisting of physiologic/ hemodynamic criteria that are a consequence of several etiologies. Confirmation of pulmonary hypertension is based on right heart catheterization. Pulmonary hypertension is a devastating condition that can lead to considerable morbidity and premature mortality. In the last few decades, significant advancement in the pharmacotherapy of pulmonary hypertension has resulted from better understanding of the complex pathogenesis and pathophysiology of this dreaded disease. Despite these accomplishments, pharmacotherapy of pulmonary hypertension is still far from perfect, and the mortality in this modern treatment era is still unacceptably high. We report a complex clinical presentation characterized by severe pulmonary hypertension secondary to concomitant mitral stenosis with veno-occlusive disease in the context of systemic sclerosis. Our case highlights the importance of a systematic and comprehensive diagnostic approach to avoid missing an underlying pathology.
{"title":"Severe Pulmonary Hypertension Secondary to Concomitant Mitral Stenosis with Veno-occlusive Disease in the Context of Systemic Sclerosis: Importance of Careful and Comprehensive Assessment","authors":"Mina Boutgourine, H. Nabawi, B. Maatof, Mohammed El-Jamili, Saloua El-Karimi, M. Hattaoui","doi":"10.9734/ca/2023/v12i4355","DOIUrl":"https://doi.org/10.9734/ca/2023/v12i4355","url":null,"abstract":"Pulmonary Arterial Hypertension (PAH) is a clinical syndrome consisting of physiologic/ hemodynamic criteria that are a consequence of several etiologies. Confirmation of pulmonary hypertension is based on right heart catheterization. \u0000Pulmonary hypertension is a devastating condition that can lead to considerable morbidity and premature mortality. In the last few decades, significant advancement in the pharmacotherapy of pulmonary hypertension has resulted from better understanding of the complex pathogenesis and pathophysiology of this dreaded disease. Despite these accomplishments, pharmacotherapy of pulmonary hypertension is still far from perfect, and the mortality in this modern treatment era is still unacceptably high. \u0000We report a complex clinical presentation characterized by severe pulmonary hypertension secondary to concomitant mitral stenosis with veno-occlusive disease in the context of systemic sclerosis. \u0000Our case highlights the importance of a systematic and comprehensive diagnostic approach to avoid missing an underlying pathology.","PeriodicalId":431606,"journal":{"name":"Cardiology and Angiology: An International Journal","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121103797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：